IP Library Granted Patent US 9,670,482
Granted Patent B2
US 9,670,482 · App. 14/091,321 · Granted Jun 6, 2017

Multispecific peptides

Inventors: Gregory Paul Winter (Cambridge, GB); Christian Heinis (Bern, CH); Elise Bernard (Cambridge, GB); David Loakes (Cambridge, GB); John Tite (Herts, GB); Marina Vaysburd (Cambridge, GB); Daniel Paul Teufel (Cambridge, GB); Lutz Riechmann (Cambridge, GB)
Assignee: BICYCLE THERAPEUTICS LIMITED
C12N15/1037A61K47/481A61K47/48246A61K47/48284C07K14/001C12N15/1044C12N15/1058C40B40/08C40B50/06G01N33/531C40B40/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,670,482
App. No.
14/091,321
Granted
Jun 6, 2017
Kind
B2
Abstract

The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.

Claims (5)

1. A multispecific peptide ligand comprising:

(a) a nucleic acid encoding the multispecific polypeptide;

(b) the multispecific peptide displayed on a phage display system, wherein the multispecific polypeptide comprises the sequence (X)IC(X)mC(X)nC(X)o (SEQ ID No. 26), wherein C represents the amino acid cysteine, X represents a random amino acid, m and n are numbers between 1 and 20 defining the length of intervening polypeptide segments and I and o are numbers between 0 and 20 defining the length of the flanking polypeptide segments;

(c) the multispecific peptide ligand encoded by the nucleic acid is linked to the nucleic acid by the phage; and

(d) the multispecific peptide ligand is attached to tris-(bromomethyl)benzene (TBMB) by three discrete covalent bonds between said TBMB and said multispecific peptide ligand via said C amino acid residues, and form at least one loop which comprises a sequence of two or more amino acids subtended between two of said C amino acid residues, wherein the multispecific peptide ligand is capable of binding to two or more targets, thus forming the multispecific peptide ligand.

Assignments (2)
CHANGE OF NAME Recorded Feb 12, 2018
From: BICYCLE THERAPEUTICS LIMITED
To: BICYCLERD LIMITED
Reel/Frame 044905/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2014
From: WINTER, GREGORY PAUL; HEINIS, CHRISTIAN; BERNARD, ELISE; LOAKES, DAVID; TITE, JOHN; VAYSBURD, MARINA; TEUFEL, DANIEL PAUL; RIECHMANN, LUTZ
To: BICYCLE THERAPEUTICS LIMITED
Reel/Frame 032434/0381 →
Priority Claims (2)
WO PCT/GB2009/000301 · Feb 4, 2009 · international
GB 0913775.3 · Aug 6, 2009 · national
Continuity (2)
Division 13147289
Related Publication 20140163201A1 · Jun 12, 2014